We are currently enrolling for Impower-024:
The main purpose of the Impower-024 study is to determine the safety and efficacy (how well it works) of an HIV drug called islatravir used for Pre-Exposure Prophylaxis (PrEP). Islatravir is in a new class of HIV medications and is taken by mouth once a month. In this study, participants will receive either monthly islatravir and a daily placebo for Descovy, or a monthly placebo and daily Descovy.
Participation will include:
- Once-a-month visits for up to 2 and a half years,
- taking either islatravir or Descovy,
- STI and HIV screening,
- giving blood and urine samples,
- doing throat and anal swabs.
You may be eligible if:
- Are a transgender woman or cisgender man,
- have anal sex with cisgender men,
- are HIV negative,
- are at least 18 years old.
For their time and travel, eligible participants can receive up to $125 per visit.
Send us a note using the form below and we’ll ring you back to see if you’re eligible for the study. It’s that simple!
